Talkspace, Inc.
NASDAQ:TALKMedical - Care Facilities
+$0.01 today
- Market cap
- $879.44M
- Beta
- 1.07
- P/E (TTM)
- 749.9
- EPS (TTM)
- $0.01
Volume 2.41M
Average 2.55M
TALK Total Current Liabilities
All obligations due within one year.
Talkspace, Inc.NASDAQ: TALK
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 19.3% from a year ago
Total current liabilities stood at $22.81M at the end of Q1 FY2026, up 19.3% from a year earlier and up 31.1% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.
Context
- Total current liabilities amounted to 16.7% of total assets at the end of Q1 FY2026, up 2.5 pp from a year earlier.
- Total current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +19.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 17.4M USD
- Year-over-year change
- -8.6%
- 4-year CAGR
- -10.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.4M | -8.6% |
| FY2024 | 2024-12-31 | 19.02M | -12.1% |
| FY2023 | 2023-12-31 | 21.65M | -20.8% |
| FY2022 | 2022-12-31 | 27.32M | +0.5% |
| FY2021 | 2021-12-31 | 27.18M | — |
Total Current Liabilities vs competitors
How TALK compares with its peers on the latest reported figures
- TALK's Mar 2026 total current liabilities of $22.81M is the 9th highest of the 11 companies compared; the peer median is $110.35M.
- Its year-over-year change of +19.3% is the 6th highest of 10, against a peer median of +21.3%.
- Total current liabilities amounts to 16.7% of total assets for TALK, versus a peer median of 17.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.57B | +8.3% | +0.3% | 19.5% | |
| Mar 2026 | $333.66M | +369.7% | +3.7% | 12.7% | |
| Mar 2026 | $195.89M | -13.1% | +16.1% | 35.8% | |
| Mar 2026 | $153.8M | +412.7% | +151.4% | 28.9% | |
| Mar 2026 | $131.2M | -4.4% | -4.7% | 12.5% | |
| Mar 2026 | $89.49M | +34.3% | +15.0% | 17.7% | |
| Dec 2025 | $57.36M | — | — | 17.1% | |
| Mar 2026 | $32.48M | +21.3% | +7.7% | 16.9% | |
| Mar 2026 | $22.81M | +19.3% | -14.0% | 16.7% | |
| Mar 2026 | $9.48M | +38.1% | +16.6% | 10.1% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $87.84K | -94.9% | -60.4% | 0.3% |
| Peer median (excluding TALK) | $110.35M | +21.3% | +7.7% | 17.0% | |
Competitors are the stored peer set for TALK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 198.26M | 138.55M | 123.91M | 76.69M | 37.35M |
| Short-term Investments | 0 | 0 | 0 | 41.12M | 55.23M |
| Net Receivables | 5.51M | 9.64M | 10.17M | 9.64M | 16.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 9.56M | 4.37M | 5.72M | 2.73M | 2.42M |
| Total Current Assets | 213.33M | 152.56M | 139.8M | 130.18M | 111.06M |
| Property, Plant & Equipment (Net) | 624K | 677K | 314K | 6.26M | 15.79M |
| Goodwill | 6.13M | 0 | 0 | 0 | 3.32M |
| Intangible Assets | 3.44M | 2.53M | 1.79M | 1.34M | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 82K | 491K | 321K | 897K | 4.69M |
| Total Non-current Assets | 10.28M | 3.7M | 2.42M | 8.5M | 23.8M |
| Total Assets | 223.61M | 156.25M | 142.22M | 138.68M | 134.86M |
| Account Payables | 7.43M | 6.46M | 6.11M | 7.71M | 8.5M |
| Short-term Debt | 0 | 200K | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.19M | 4.36M | 3.07M | 3.28M | 2.22M |
| Other Current Liabilities | 6.57M | 11.01M | 5.2M | 2.39M | 6.67M |
| Total Current Liabilities | 27.18M | 27.32M | 21.65M | 19.02M | 17.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.16M | 1.1M | 1.93M | 2.26M | 452K |
| Total Non-current Liabilities | 4.16M | 1.4M | 1.93M | 2.26M | 452K |
| Total Liabilities | 31.33M | 28.72M | 23.58M | 21.28M | 17.85M |
| Common Stock | 15K | 16K | 16K | 17K | 17K |
| Retained Earnings | (171.53M) | (251.2M) | (270.38M) | (269.24M) | (261.44M) |
| Accumulated OCI | (223.61M) | 0 | 0 | 2K | 57K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 192.27M | 127.54M | 118.65M | 117.4M | 117.02M |
| Total Debt | 0 | 500K | 0 | 0 | 0 |
| Net Debt | (198.26M) | (138.05M) | (123.91M) | (76.69M) | (37.35M) |
Talkspace, Inc.
NASDAQ:TALK
Intrinsic Alpha fair value
Locked
Current Price
$5.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.